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Abstract
Background: The present study was performed to assess the prognosis of patients admitted to the intensive care
unit (ICU) for community acquired pneumonia (CAP) after implementation of new processes of care.
Methods: Two groups of patients with CAP were admitted to a 16-bed multidisciplinary ICU in an urban teaching
hospital during two different periods: the years 1995–2000, corresponding to the historical group; and 2005–2010,
corresponding to the intervention group. New therapeutic procedures were implemented during the period
2005–2010. These procedures included a sepsis management bundle derived from the Surviving Sepsis Campaign,
use of a third-generation cephalosporin and levofloxacin as the initial empirical antimicrobial regimen, and
noninvasive mechanical ventilation following extubation.
Results: A total of 317 patients were studied: 142 (44.8%) during the historical period and 175 (55.2%) during the
intervention period. Sequential Organ Failure Assessment scores were higher in patients in the intervention group
(7.2 ± 3.7 vs 6.2 ± 2.8; p=0.008). Mortality changed significantly between the two studied periods, decreasing from
43.6% in the historical group to 30.9% in the intervention group (p < 0.02). A restrictive transfusion strategy, use of
systematic postextubation noninvasive mechanical ventilation in patients with severe chronic respiratory or cardiac
failure patients, less frequent use of dobutamine and/or epinephrine in patients with sepsis or septic shock, and
delivery of a third-generation cephalosporin associated with levofloxacin as empirical antimicrobial therapy were
independently associated with better outcomes.
Conclusion: Positive outcomes in ICU patients with CAP have significantly increased in our ICU in recent years.
Many new interventions have contributed to this improvement.
Keywords: Severe community acquired pneumonia, Intensive care unit, Antimicrobial therapy,
Combination therapy
Background
Severe community-acquired pneumonia (SCAP) is one
of the leading causes of intensive care unit (ICU) admis-
sion among septic patients [1]. The mortality rate of
SCAP is reportedly as high as 40% [2]. Inadequate anti-
biotic treatment, septic shock, acute lung injury, and as-
sociated comorbidities are the main factors contributing
to this poor prognosis. In consideration of evolving epide-
miologic data and the development of new antibiotics,
numerous guidelines are regularly published to help physi-
cians optimize delivery of antimicrobial treatment in pa-
tients with SCAP [3-6]. At the beginning of the previous
decade, many studies reported a decrease in the mortality
of ICU patients by adopting new therapeutic strategies:
limitation of tidal volume and ventilatory pressure in pa-
tients with acute lung injury [7], delivery of low-dose
hydrocortisone in patients with septic shock [8], use of in-
tensive insulin therapy [9], a restrictive strategy of red cell
transfusion [10], treatment with drotrecogin alpha [11]
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and the systematic use of noninvasive mechanical ventila-
tion (NIMV) following extubation [12]. During the year
2004, new recommendations concerning the acute man-
agement of sepsis and septic shock were proposed in
the Surviving Sepsis Campaign (SSC) guidelines [13].
Key recommendations established by international critical
care and infectious disease experts included initial resusci-
tation, diagnostic studies, sepsis source control, antibiotic
delivery, fluid administration, inotropic and vasopressor
therapies, blood product administration, mechanical ventila-
tion, steroids, and glucose control. Some of these proposals
were introduced into daily practice in our unit according to
this publication. During this same period, our local antibiotic
policy changed to the combination of a third-generation
cephalosporin (3rdGC) and antipneumococcal fluoroquino-
lone for the empirical treatment of SCAP. This choice was
supported a few months later by the Société de Pathologie
Infectieuse de Langue Française guidelines and the Infec-
tious Diseases Society of America recommendations [5,6].
The goal of our study was to compare the outcome of
patients with SCAP during 1995–2000 with that during
2005–2010, where new processes of care were implemented.
Methods
Setting and design
A before-and-after study design was employed. Two groups
were defined. The first period included all consecutive
patients with SCAP admitted between January 1995 and
December 2000 (historical group). The second period in-
cluded all consecutive patients with SCAP admitted be-
tween January 2005 and December 2010 (intervention
group). The "4-year" hiatus corresponded to the progres-
sive implementation of the new therapeutic strategies.
The Ethics Committee of Tourcoing Hospital approved
the study and waived the need for written informed con-
sent in agreement with French regulations concerning
retrospective studies (N°2011-01).
Patients
All patients ≥ 18 years of age who presented with CAP
during the two studied periods were included. CAP was
defined as the presence of a new pulmonary infiltrate on
a chest radiograph at the initial presentation or that oc-
curring within 48 hours following hospitalization along
with the acute onset of two or more of the following
signs or symptoms: fever, new or increasing cough or
sputum production, dyspnea, pleuritic chest pain, new
focal signs on chest examination, and leukocytosis or
leukopenia as defined by local laboratory values. Patients
were admitted to the ICU for mechanical ventilation
(MV), for vasoactive drug support, or because the clin-
ician believed that the individual was otherwise unstable
and required intensive medical care. Patients were ex-
cluded for the following reasons: diagnosis of aspiration
pneumonia, diagnosis of pneumocystis pneumonia, and
if the Pneumonia Severity Index (PSI) score were ≤III
[14]. For patients with more than one admission for
CAP in our unit, only the first admission was taken into
account.
Data collection
Collected baseline characteristics were age, gender, alco-
holism, chronic obstructive pulmonary disease (COPD),
congestive heart failure, cancer, immunosuppression,
functional status, and diabetes mellitus. The diagnosis of
COPD was based on the clinician’s assessment and in-
cluded data provided by patients or relatives and found
on previous medical reports. Congestive heart failure
was defined as New York Heart Association (NYHA)
class IV [15]. Functional status was assessed by the
Knaus score [16]. Immunosuppression was defined as a
recent use of immunosuppressants or systemic cortico-
steroids (i.e., prednisolone at >0.5 mg/kg/day for more
than 1 month), human immunodeficiency virus infec-
tion, neutropenia (absolute neutrophil count of <1000
cells/mm3), organ transplantation with ongoing immuno-
suppressants, or cancer chemotherapy within the past 3
months. Patients with cancer were defined as those pre-
senting with a diagnosis of a solid tumor or hematologic
malignancy within 5 years of ICU admission.
Clinical and biological parameters collected upon ICU
admission were the Simplified Acute Physiology Score
(SAPS II) [17], Sequential Organ Failure Assessment
(SOFA) score [18], PSI risk class, admission to the ICU
within 24 hours after hospital admission, leukopenia
(leukocyte count of <4000/mm3), PaO2:FIO2 in patients
undergoing MV, an etiological diagnosis of pneumonia, and
associated bacteremia. An etiologic diagnosis was consi-
dered when pathogens were isolated from (1) blood cul-
tures, (2) pleural fluid, (3) sputum samples (bacterial
growth in culture of endotracheal aspiration sample of
≥105cfu/mL in intubated patients), (4) a four-fold rise in IgG
titers for Legionella pneumophila, Chlamydia pneumoniae,
or Mycoplasma pneumoniae, (5) a single increased IgM titer
for M. pneumoniae (≥1:16), Chl. pneumoniae (≥1:32), or
Coxiella burnetii (≥1:64) or (6) positive urinary antigens for
L. pneumophila type 1 or Streptococcus pneumoniae (tests
performed during the second period of the study).
The recorded data on therapeutics performed within
48 hours after ICU admission were the class of delivered
antimicrobial agents, antimicrobial combination therapy,
adequacy of antimicrobial therapy, institution of anti-
microbial therapy within 8 hours after hospital admis-
sion, NIMV and/or IMV, crystalloid or colloid fluid
administration (first 24 hours after ICU admission), and
requirement and nature of vasoactive agents. Antimicro-
bial therapy was considered to be adequate if the causa-
tive pathogens were susceptible to at least one of the
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delivered antimicrobial agents as shown on the antibiotic
susceptibility reports. The recorded vasoactive drugs were
dobutamine, dopamine, norepinephrine and epinephrine.
The recorded data on characteristics of the ICU stay were
the mean tidal volume during the first 3 days of MV, trans-
fusion requirement, occurrence of nosocomial infection,
duration of MV, duration of ICU stay, and ICU mortality.
Recorded nosocomial infections were ventilator-associated
tracheobronchitis, ventilator-associated pneumonia, and
bacteremia. Ventilator-associated tracheobronchitis, venti-
lator-associated pneumonia were defined according to pre-
vious reports [19,20].
Standard process of care during the two studied periods
Historical period
Vasoactive drugs: Pulmonary arterial catheterization
was performed in patients with septic shock. The
choice of vasopressor agents was left to each physician.
Dobutamine was prescribed to increase oxygen delivery
because it was the practice at that time [21].
Fluid therapy: Intravascular volume loading was
assessed by physical examination and/or pulmonary
arterial catheterization.
Insulin therapy: Insulin therapy was only prescribed for
patients with diabetes mellitus who required insulin
therapy at home.
MV: A tidal volume of 8 to 10 mL/kg was delivered after
starting MV. The tidal volume was then modified
according to the acid- base status, without specific
limitations on the increase in the tidal volume.
Transfusion requirement: A hemoglobin level of ≥10 g/dL
was required because of its widespread use in clinical
medicine [22].
NIMV following extubation: NIMV was only used as
rescue therapy when respiratory distress followed
extubation.
Antimicrobial therapy: Our local hospital policy
suggested treatment of SCAP with a beta-lactam plus
fluoroquinolone according to the French
recommendations published at the time [23]. The beta-
lactam was chosen by physicians among amoxicillin
(50 mg/kg/d), amoxicillin/clavulanate (50 mg/kg/d),
cefotaxime (50 mg/kg/d), or ceftriaxone (2 g/d). The
fluoroquinolone was similarly chosen between ofloxacin
(400 mg/d) or ciprofloxacin (800 mg/d).
Intervention period
New processes of care were progressively introduced in
the unit during the period 2001_2004. An educational pro-
gram based on the SSC guidelines was next implemented
in our unit over a 1-month period (December 2004). The
procedures were then written and made available to each
physician in the unit.
Vasoactive drugs: The recommended vasopressor was
norepinephrine. Dobutamine was only considered for
patients with a low cardiac output in the presence of
adequate left ventricular filling pressure and adequate
mean arterial pressure as schown by echocardiography.
The use of dobutamine for supranormal oxygen
delivery was discontinued.
Fluid therapy: Intravascular volume loading was
assessed by physical examination and/or arterial pulse
pressure and/or echocardiography. Fluid responsiveness
was determined by respiratory variations in the
superior and inferior vena cava diameters, left
ventricular stroke, and arterial pulse pressure [24].
Stress-dose steroid: Intravenous hydrocortisone was
instituted in all septic patients who required
vasopressor use.
Transfusion requirement: A restrictive red blood cell
transfusion strategy was adopted targeting a
hemoglobin level of 7 to 9 g/dL in all patients with the
exception of those with acute myocardial infarcts or
unstable angina, for whom a level of 10 g/dL level was
required.
Low tidal volume: A tidal volume of 6 mL/kg was
started in all patients undergoing MV. The tidal
volume was then modified following blood gas analysis.
Maintenance of an end-inspiratory plateau pressure of
no more than 30 cm of H2O was a strict goal.
Insulin therapy: Insulin therapy was started in all
patients to maintain a blood glucose level of
<150 mg/dL.
NIMV: After a successful spontaneous breathing trial,
NIMV was instituted within the next 24 hours
following extubation procedures in patients with severe
COPD (long-term oxygen therapy and noninvasive
ventilation at home) and in patients with chronic
cardiac failure (NYHA class IV).
Antimicrobial therapy: Between the two studied
periods, our hospital guideline for empirical
antimicrobial therapy in patients with CAP was
modified according to international recommendations
[25]. A combination of a 3rdGC (cefotaxime or
ceftriaxone) and a respiratory fluoroquinolone
(levofloxacin) was suggested. Levofloxacin was
discontinued after 3 days of delivery if Legionella
urinary antigen tests remained negative.
Years 2001–2004
Age, SAPS II, number of patients with MV or vasopressor
support, and mortality for all CAP patients with CAP
admitted to our unit during this period were reported.
Statistical analysis
The two studied groups were compared using the chi-
squared test or Fisher٫s exact test for categorical parameters
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and Student’s t test for continuous variables. When appropri-
ate, continuous variables were analyzed as categorical vari-
ables using clinically meaningful cut-off points.
The first objective of the study was to assess the mor-
tality of patients during the two studied periods.
The second objective was to determine prognostic fac-
tors associated with outcome. We performed a univari-
ate analysis including all patients to assess risk factors
for mortality. Differences between the two studied
groups were considered to be significant for variables
Table 1 Management of patients with severe CAP
Historical Intervention
Group Group p
n=142 (44.8) n=175 (55.2)
Patients characteristics
Age, yrs 65.7 ± 14.4 64.2 ± 15.7 0.39
Male, n (%) 109 (75.7) 114 (65.1) 0.02
Alcoholism, n (%) 39 (27.4) 48 (27.4) 0.99
COPD, n (%) 69 (48.6) 63 (36) 0.02
Chronic cardiac failure, n (%) 19 (13.4) 27 (15.4) 0.60
Diabetes mellitus, n (%) 15 (10.6) 28 (16) 0.15
Cancer, n (%) 4 (2.8) 14 (8) 0.04
Immunosuppression, n (%) 8 (5.6) 34 (19.4) 0.0003
Knaus score, n (%) 0.18
A 11 (7.7) 21 (12)
B 45 (31.7) 69 (39.4)
C 74 (52.1) 72 (41.4)
D 12 (8.4) 13 (7.3)
ICU admission
Within 24 hrs of hospital admission, n (%) 112 (78.9) 127 (72.6) 0.19
SAPS II 47.8 ± 16.3 48.7 ± 19.7 0.67
SOFA score 6.2 ± 2.8 7.2 ± 3.7 0.008
PSI risk class V, n (%) 93 (65.5) 118 (67.4) 0.71
Leukopenia, n (%) 17 (12) 13 (7.4) 0.16
Hemoglobin level (g/dL) 12.7 ± 2.5 11.8 ± 2.3 0.001
PaO2:FIO2 < 200 in patients with MV, n (%) 84 (78.5) 85 (66.4) 0.04
Documented pneumonia, n (%) 86 (60.6) 100 (57.1) 0.53
Pathogens*
Streptococcus pneumoniae, n (%) 45 (52.3) 63 (63) 0.42
Streptococcus pneumoniae with DSP, n (%) 18 (20.9) 17 (17) 0.40
Staphylococcus aureus, n (%) 12 (13.9) 5 (5) 0.02
Enterobacteriacea, n (%) 11 ( 12.8) 12 (12) 0.76
Haemophilus Influenzae, n (%) 12 (13.9) 11 (11) 0.45
Pseudomonas aeruginosa, n (%) 4 (4.6) 2 (2) 0.29
Legionella pneumophila, n (%) 1 (1.1) 7 (7) 0.06
Other, n (%) 6 (6.9) 7 (7) 0.91
Bacteremia, n (%) 19 (13.6) 34 (19.4) 0.16
Results are mean ± SD unless indicated otherwise.
COPD, chronic obstructive pulmonary disease; ICU, intensive care unit.
SAPS, simplified acute physiology score; SOFA, sequential organ failure assessment score.
PSI, pneumonia severity index; DSP, decreased susceptibility to penicillin.
* Some pneumonia are caused by many pathogens.
Comparison upon ICU admission between historical controls (1995_2000) and current strategies (2005_2010).
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yielding a p value of ≤0.05. To study the relationship be-
tween mortality and any predictor while taking the sig-
nificant variables into account, we performed three
stepwise logistic regressions as follows. The significant
variables collected within 48 hours of admission were
used for the first analysis, the therapeutic procedure in-
stituted upon ICU admission and during the ICU stay
were used for the second analysis, and all significant var-
iables were entered into a third stepwise analysis. A level
of p ≤0.15 was chosen for covariate retention.
The third objective of the study was to analyze the
evolution of the SOFA score during the first week of
ICU admission with a linear mixed model.




A total of 317 patients were admitted to our ICU for CAP
during the two studied periods: 142 (44.8%) during the
historical period and 175 (55.2%) during the intervention
period. Baseline characteristics and presentation upon
ICU admission in the two groups are reported in Table 1.
A total of 127 patients with CAP were admitted to our
ICU during the years 2001–2004.
Mean age and mean SAPS II were 65.1 ± 15.3 years
and 50.5 ± 19.7, respectively. Among these patients, 93
(73.2%) underwent MV and 66 (51.9%) required vaso-
pressor support. Fifty-three (41.7%) patients died.
Process of care
Therapeutic interventions upon ICU admission and
during the ICU stay are reported in Table 2. As expected,
the intervention period was characterized by MV with a
lower tidal volume, lower transfusion requirement, more
intravascular volume expansion, lower use of dobutamine,
more frequent postextubation NIMV procedures and
more frequent norepinephrine use in patients with
septic shock. Low-dose steroid administration was in-
stituted in 81.6% of patients requiring vasoactive
drugs, and intensive insulin therapy was delivered in
86.3% of patients.
Antibiotic administration in each period is presented
in Table 3. Among beta-lactams, 3rdGCs were more fre-
quently used than aminopenicillins during the interven-
tion period (78% vs. 50.4%, p < 0.001).
Table 2 Management of patients with severe CAP
Historical Intervention
Group Group p
n=142 (44.8) n=175 (55.2)
NIMV within 48 hrs of admission, n (%) 26 (18.3) 35 (20) 0.7
MV within 48 hrs of admission, n (%) 106 (74.6) 127 (72.6) 0.18
Fluid administration within 24 hours of admission, ml 1300 ± 1900 2200 ± 1700 < 0.0001
Vasoactive drugs within 48 hrs of admission, n (%) 74 (52.2) 109 (62.3) 0.07
Dobutamine, n (%) 46 (32.4) 17 (9.7) < 0.0001
Dopamine, n (%) 8 (5.6) 10 (5.7) 0.97
Norepinephrine, n (%) 19 (13.4) 105 (57.7) < 0.0001
Epinephrine, n (%) 20 (14.1) 11 (6.3) 0.02
Dual therapy, n (%) 121 (85.2) 158 (90.3) 0.16
Adequate antimicrobial therapy/ documented pneumonia, n (%) 82 (96.4) 92 (92) 0.20
Antimicrobial therapy within 8 h of admission, n (%) 109 ( 76.7) 138 (78.8) 0.65
Combination of a 3rdGC and levofloxacin, n (%) 0 115 (65.7) < 0.0001
Insulin therapy, n (%) 19 (13.4) 151 (86.3)
Intensive insulin therapy, n (%) 0 151 (86.3) < 0.0001
Mean tidal volume, mL/kg 8.17 ± 1.19 6.64 ± 0.73 < 0.0001
Low-dose steroid administration, n (%) 0 89 (50.8) < 0.0001
Transfusion, n (%) 62 (43.7) 40 (22.8) < 0.0001
Number of red blood cell units transfused per patient 2.6 ± 4.5 0.8 ± 2.1 < 0.0001
Systematic postextubation NIMV, n (%) 8 (5.6) 20 (11.4) 0.07
Results are mean ± SD unless indicated otherwise.
NIMV, non invasive mechanical ventilation; MV, mechanical ventilation.
3rdGC, third generation cephalosporin.
Therapeutics interventions during the two studied periods, historical controls (1995–2000) and current strategies (2005–2010).
Georges et al. BMC Infectious Diseases 2013, 13:196 Page 5 of 10
http://www.biomedcentral.com/1471-2334/13/196
Outcome and prognostic factors
Between the two studied populations, 116 (36.6%) pa-
tients died. The prognosis of patients improved during
the intervention period: 62 (43.6%) patients died during
the historical period, and 54 (30.9%) patients diedduring
the intervention period (p < 0.02). Mortality remained
high during the years 2001–2004; 53 (41.7%) patients
with CAP died. Significant prognostic factors between
survivors and nonsurvivors are reported in Table 4. A
reduction in the evolution of the SOFA score during the
first week following ICU admission was noted during
the intervention period (p < 0.001) (Figure 1). The dur-
ation of MV, duration of ICU stay and occurrence of noso-
comial infection were not different between the historical
and intervention periods (10.7 ± 13.3 vs.10.8 ± 13.7 days,
p = 0.96; 13.4 ± 14.4 vs 13.2 ± 13.6 days, p = 0.88; and 41
(20.4%) vs. 32 (27.6%), p = 0.14, respectively).
Multivariate analysis
Results are presented in Table 5. Admission during the
intervention period was independently associated with a
better prognosis (p = 0.001). The multivariate analyses
underscore several poor prognostic factors related to pneu-
monia severity upon ICU admission: SAPS II > 50, require-
ment for vasoactive drugs, and a PSI risk class of V.
Among therapeutic procedures, dobutamine and adrenaline
use, low-dose steroid administration, and a transfusion re-
quirement were associated with a worse prognosis. In con-
trast, administration of the combination of a 3rdGC and
levofloxacin as an empirical antimicrobial regimen and sys-
tematic postextubation NIMV improved outcomes.
Discussion
The main result of our study is that in our unit, the
mortality of patients with CAP was reduced from 43.6%
to 30.9%. We demonstrated that compliance with some
components of the bundles derived from the SSC guide-
lines was associated with a significant improvement in
the outcome of patients with CAP. Our report confirms
the feasibility of changing the quality of care in patients
with severe sepsis or septic shock using new, easily ap-
plicable therapies. In the same way, our study supports
the hypothesis that the use of empirical antimicrobial
therapy concordant with national clinical practices is as-
sociated with improvement in outcomes.
The mortality in the first period may appear high com-
pared with that in some studies published at the same
time [26,27]. However, our patients were more severely
ill; most required MV and exhibited septic shock. Two
recent studies evaluating the clinical and economic bur-
den of CAP in Europe reported an ICU mortality
reaching 45% [2,28]. Our results are even more signifi-
cant considering that the severity of disease upon ICU
admission was nearly identical between the two groups.
There were no differences in SAPS II, PSI class V,
leukopenia, bacteremia, delay of ICU admission, use of
MV, or vasoactive drug support. SOFA scores were sig-
nificantly higher in the intervention group. Causative
pathogens changed little during the two periods. The in-
cidence of penicillin-nonsusceptible S. pneumoniae did
not vary. Staphylococcus aureus infection was more fre-
quent in the historic group but probably had no impact
on outcome because no strains were methicillin-resistant.
The combination of a 3rdGC with a respiratory fluoro-
quinolone is among the new interventions associated with
improvement in outcomes. This association seems attract-
ive, allowing for the delivery of two antipneumococcal
drugs with high bactericidal activity and excellent tissue
penetration. Drago recently reported that among numer-
ous combinations of fluoroquinolones or macrolides, the
combination of levofloxacin with a parenteral cephalo-
sporin was the most active against S. pneumoniae strains
[29]. The antipneumococcal activity of levofloxacin could
explain the improvement in outcomes; the patients bene-
fited from a “true” combination therapy against the main
causative pathogen of CAP. This association could be a
major advantage in the most severe forms of pneumococ-
cal disease. This result confirms that of a previous report
in which we showed that when combined with beta-
lactams, levofloxacin is associated with lower mortality








Amoxicillin, n= 4 2
Amoxicillin clavulanate, n= 10 5
Cetotaxime or Ceftriaxone, n= 7 7
Other, n= - 3
Combination therapy 121 158
Amoxicillinc and Ofloxacin, n= 10 0
Amoxicillin and Ciprofloxacin, n= 1 0
Amoxicillin clavulanate and Ofloxacin, n= 29 4
Amoxicillin clavulanate and Ciprofloxacin, n= 11 0
Cetotaxime or Ceftriaxone and Ofloxacin, n= 49 9
Cetotaxime or Ceftriaxone and
Ciprofloxacin, n=
5 0
Amoxicillin and Levofloxacin, n= 0 1
Amoxicillin clavulanate and Levofloxacin, n= 0 12
Cetotaxime or Ceftriaxone and
Levofloxacin, n=
0 115
Other combination, n= 16 17
Antibiotics delivered according to studied period; historical controls (1995–2000)
and current strategies (2005–2010).
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than ofloxacin or ciprofloxacin in patients with severe
pneumococcal CAP [30]. Other studies have reported op-
posing results with a combination of beta-lactams and
fluoroquinolones, but studied patients, delivered fluoro-
quinolones (ciprofloxacin) and treatment duration of
fluoroquinolones were not identical [31,32]. The first-line
empirical beta-lactam differed between the two stu-
died periods in that a 3rdGC was used in place of
aminopenicillins. In both cases, however, the drug used
was the drug recommended for the treatment of CAP at
the time [3,23]. Our results support the most recent Infec-
tious Diseases Society of America guideline suggesting that
the combination of levofloxacin and a beta-lactam repre-
sents a better option with which to treat patients with CAP
in the ICU (level I evidence) [5].
The use of NIMV as a systematic extubation and
weaning technique was first proposed in patients with
chronic respiratory failure [12]. Subsequent studies pro-
posed the use of NIMV in patients with risk factors for
respiratory failure after extubation [33,34]. NIMV offsets
muscle fatigue and tachypnea, increases tidal volume
and reduces intrinsic positive and expiratory pressure.
During the intervention period of the present study, we
applied NIMV after a successful T-piece weaning trial in
extubated patients with severe underlying COPD or se-
vere chronic cardiac failure. When this procedure was
well tolerated, NIMV was delivered by face mask, spaced
by periods of spontaneous ventilation, for at least 24 hours.
Many studies have indicated that blood transfusion in
critically ill patients is associated with worse outcome
[35]. Critically ill patients may be at increased risk for the
immunosuppressive and microcirculatory complications
of blood transfusion. In the absence of acute bleeding,
Table 4 Significant prognostic factors derived from univariate analysis
Survivors Non survivors
n = 201 n = 116 p
Patient characteristics
Age, yrs 62.9 ± 15.3 68.5 ±14.4 0.001
ICU admission
SAPS II 40.8 ± 12.0 61.3 ± 19.9 < 0.001
SOFA score 5.7 ± 5.3 8.6 ± 3.5 < 0.001
PSI class V, n (%) 108 (53.7) 103 (88.8) < 0.001
Leukopenia, n (%) 10 (5) 20 (17.2) < 0.001
MV within 48 hrs of admission, n (%) 124 (61.7) 109 (94) < 0.001
PaO2:FIO2 < 200 in patients with MV, n (%) 76 (37.8) 93 (80.2) < 0.001
Therapeutics interventions
Vasoactive drugs within 48 hrs of admission, n (%) 88 (43.8) 95 (81.9) < 0.001
Dobutamine, n (%) 26 (12.9) 37 (31.9) < 0.001
Dopamine, n (%) 7 (3.5) 11 (9.5) 0.02
Norepinephrine, n (%) 66 (32.8) 54 (46.5) 0.01
Epinephrine, n (%) 7 (3.5) 24 (20.7) < 0.001
Combination of a 3rdGC and levofloxacin, n (%) 84 (41.8) 31 (26.7) 0.007
Mean tidal volume, mLl/kg 7.14 ± 1 7.56 ± 1.41 0.008
Low-dose steroid administration, n (%) 47 (23.3) 42 (36.2) 0.01
Transfusion, n (%) 48 (23.9) 54 (46.5) < 0.001
Systematicpost extubation NIMV, n (%) 21 (10.4) 7 (6) 0.01
Intervention period, n (%) 121 (69.1) 54 (30.8) 0.01















Figure 1 Evolution of the SOFA score during the first week
following ICU admission.
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hemoglobin levels of 70 to 90 g/L are well tolerated by
most critically ill patients and a transfusion threshold of
70 g/L is now considered appropriate. In our study, des-
pite a higher average hemoglobin concentration in the
historical group, the number of patients transfused and
the number of red blood cell units transfused per patient
were higher in this group. Our results support the poten-
tial benefits of a restrictive transfusion strategy in pa-
tients with severe sepsis [10].
During the intervention period, 81.6% of patients with
septic shock received steroids. Low-dose steroid adminis-
tration is associated with a worse prognosis. The use of
corticosteroids in the treatment of sepsis or septic shock
remains controversial [8,36]. Discontinuation of steroids
could lead to a rebound of the inflammatory response and
an increased incidence of rebound sepsis. We did not per-
form a 250-μg ACTH stimulation test to identify re-
sponders; thus, steroids were probably overused, notably in
patients who received low-dose vasopressor therapy. In
2008, the second SSC guidelines recommended the use of
steroid therapy only when blood pressure is poorly respon-
sive to fluid replacement and vasopressor therapy [37].
Norepinephrine administration was more frequent and
dobutamine administration was less frequent during the
intervention period than during the historical period. In
2004, Leone reported a lack of standardization in the use
of catecholamines by French physicians [38]. Our study
shows an association between the use of epinephrine
and unfavorable outcomes. Human and animal studies
have suggested that epinephrine has deleterious effects
on the splanchnic circulation [39].
Our study has limitations. First, our analysis was retro-
spective, and the possibility that the type of patients se-
lected changed over time cannot be excluded. Second,
the high number of changes in practice throughout the
time course of the study limits our ability to determine a
causal relationship between new therapeutic interven-
tions and the outcome we evaluated. Most notably, some
therapeutics, such as the combination of a 3rdGC and
levofloxacin have been prescribed only recently, and
studies with a different methodological approach are ne-
cessary to confirm our results. Third, pneumonia sever-
ity upon ICU admission was higher in the second
period, and we cannot exclude the possibility that the
change in ICU triage and admission practice patterns
between the two time periods caused patients at higher
risk of imminent death to be triaged away from ICU care
at a higher rate. However, this probably concerned few
patients. Indeed, life-sustaining treatments and palliative
care for critically ill patients are generally delivered in
our unit rather than in the emergency department.
Fourth, the medical staff experienced substantial turn-
over during the studied periods and we cannot exclude
the possibility that staff members were more experi-
enced during the intervention stage. Fifth, this was a
single-center study, and these results may not be extrap-
olated to other hospitals. Finally, our study predomin-
antly applies to elderly male patients, this demographic
was the most commonly represented.
Because mortality remains high, other therapies as well
as a more rapid diagnosis and management in the emer-
gency department are necessary. The anti-inflammatory
effects of statins, the use of biomarkers to predict early
treatment failure, and high-flow nasal therapy to reduce
intubation require further study.
Conclusions
Management of patients with CAP requiring ICU admis-
sion has evolved in recent years. In our unit, many new
procedures concerning associated sepsis management and
delivery of empirical antimicrobial therapy have been insti-
tuted according to successive published guidelines. These
implementations were accompanied by improvements in
outcomes. Delivery of a the combination of a 3rdGC and
levofloxacin as initial empirical antimicrobial therapy and
a restrictive transfusion strategy targeting a hemoglobin
level of 7 to 9 g/dL are the main new therapeutic proce-
dures contributing to this improvement.
Table 5 Management of patients with severe CAP
Variables Adjusted
OR
95% CI p Value
Admission data
SAPS II > 50 4.21 2.35-7.56 < 0.0001
Vasoactive drugs within 48 hrs
of admission
2.91 1.51-5.61 0.0001
PSI class V 2.70 1.3- 5.6 0.007
Historical period 2.53 1.42-4.52 0.001
Therapeutics interventions
Epinephrine use 4.97 1.96-12.6 0.0007
Low-dose steroid administration 2.29 1.18-4.46 0.01
Dobutamine 2.12 1.09-4.11 0.02
Transfusion 1.92 1.07-3.44 0.02
Combination of a 3rdGC and
levofloxacin
0.37 0.19-0.74 0.004
Systematic postextubation NIMV 0.30 0.11-0.82 0.01
Whole data
SAPS II > 50 3.51 1.89-6.51 < 0.0001
PSI risk class V 2.73 1.23-6.04 0.01
Vasoactive drugs within 48 hrs
of admission
2.48 1.21-5.08 0.01
Transfusion 1.97 1.06-3.65 0.03
Combination of a 3rdGC and
levofloxacin
0.36 0.18-6.51 0.002
Systematic postextubation NIMV 0.34 0.12-0.95 0.03
Multiple logistic regressions of factors associated with poor outcome.
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